Literature DB >> 313108

Cyclophosphamide-sensitive and cyclophosphamide-resistant suppressor cells in the immune response to alloantigens.

B Bonavida, I V Hutchinson, A Thomas.   

Abstract

We have demonstrated that within a given system Cy may alter the immune response in different ways. It may augment the response by inactivating CSS cells or induce immunosuppression by activating CRS. Furthermore, our studies provide a means of analyzing the mechanism of suppression, that is, delineating the target cell for suppression, the properties and life span of the suppressed cells, and the nature of the cell interactions involved. Furthermore, with the available information on the immunosuppressive activity of Cy, clinical studies may be best monitored in transplantation immunology and tumor chemotherapy. It is possible that the induction of CRS cells, which are antigen-nonspecific and non-H-2-restricted, may be useful for inducing specific immunosuppression to alleviate GVH reactions. These studies are currently in progress.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 313108

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  After chemotherapy, functional humoral response capacity is restored before complete restoration of lymphoid compartments.

Authors:  A Zandvoort; M E Lodewijk; P A Klok; M A Breukels; G T Rijkers; W Timens
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

2.  A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.

Authors:  D W Miles; K E Towlson; R Graham; M Reddish; B M Longenecker; J Taylor-Papadimitriou; R D Rubens
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

3.  Regulatory T cells in radiotherapeutic responses.

Authors:  Dörthe Schaue; Michael W Xie; Josephine A Ratikan; William H McBride
Journal:  Front Oncol       Date:  2012-08-17       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.